What BridgeBio Pharma, Inc. does.

BridgeBio Pharma, Inc. is a commercial-stage, multi-product biopharmaceutical company organized around a portfolio operating model to discover, develop, and deliver medicines for patients with genetic diseases. We seek to translate advances in genetic science into therapies for patient populations with significant unmet medical needs.

Since our founding 10 years ago, we have advanced multiple programs from discovery through regulatory approval and commercialization. To date, more than 8,500 patients have been treated with our approved medicines, and we have obtained U.S. Food and Drug Administration (the “FDA”) approval for three products. We believe our decentralized hub and spoke model enables us to achieve clinical proof-of-concept with speed and efficiency, demonstrated by an average investment per program of less than $40.0 million to proof-of-concept data and less than $10.0 million to reach Investigational New Drug (“IND”) submission. This efficiency allows us to work on a broad range of scientifically compelling therapies, including programs for underserved conditions which more traditional biopharmaceutical models might leave on the shelf but we believe can be developed on a Net Present Value (“NPV”)-positive basis in our portfolio.

Revenue and profit, by fiscal year.

More on BBIO.

• BridgeBio Pharma, Inc. summary
• BridgeBio Pharma, Inc. financial statements
• BridgeBio Pharma, Inc. key metrics
• BridgeBio Pharma, Inc. health scores and style box
• BridgeBio Pharma, Inc. earnings
• BridgeBio Pharma, Inc. dividends
• BridgeBio Pharma, Inc. valuation
• BridgeBio Pharma, Inc. ownership and insiders
• BridgeBio Pharma, Inc. peers

Figures from BridgeBio Pharma, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.